Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
761.130.03%
QQQ
709.610.06%
BTC/USD
77190.001.2818%
DIA
524.660.03%
GLD
393.070.06%
TLT
80.93-

Sabra Health Care REIT Inc

SBRANASDAQ
Trade with Public
Trade with Public
$20.50
-0.02-0.1%
At close: Sep 14, 5:00 PM EST
$20.49
-0.01-0.05%
After Hours: 6:35 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipDividendsCompareOptionsStock Report

Sabra Health Care REIT Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sabra Health Care REIT (SBRA).

Price Target Range — 13 Quarters

Analyst Consensus — 18 Analysts

3S.Buy
7Buy
8Hold
Consensus RatingNeutral# Analysts18Avg. Consensus PT$20Upside to Avg. PT-0.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 31, 2026BarclaysRichard HightowerPT RaiseEqual-Weight$21→$23
Aug 31, 2026BairdVikram MalhotraPT RaiseNeutral$20→$21
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23

Barclays analyst Richard Hightower maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Equal-Weight and raises the price target from $21 to $23.
Benzinga Newsdesk

PRO
Baird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $21

Baird analyst Vikram Malhotra maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and raises the price target from $20 to $21.
Benzinga Newsdesk

This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Wall Street analysts change outlook on top names. See all rating changes, upgrades, downgrades and initiations at Benzinga's analyst ratings page.
Avi Kapoor

PRO
Raymond James Upgrades Sabra Health Care REIT to Market Perform

Raymond James analyst David Rodgers upgrades Sabra Health Care REIT (NASDAQ:SBRA) from Underperform to Market Perform.
Benzinga Newsdesk

PRO
Baird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $23

Baird analyst Wesley Golladay maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and raises the price target from $22 to $23.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Sabra Health Care REIT, Raises Price Target to $24

Truist Securities analyst Michael Lewis maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Buy and raises the price target from $22 to $24.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved